PeriRx kicks off 2015 with debut at Yankee Dental Congress
PeriRx LLC, a premier developer of breakthrough, noninvasive, oral diagnostic technology, will kick off 2015 with its first-time participation at the first major dental meeting of the year, The Yankee Dental Congress in Boston. The company will be exhibiting at booth No. 1746 from January 29th to January 31st.
The mortality rate for oral cancer is alarmingly high, with more than 8,000 deaths every year which equates to one person dying every hour, 24 hours per day. (2) “Earlier detection via molecular DNA testing can reverse these statistics,” added Swanick.
ADDITIONAL READING |Human papillomavirus and oral cancer
More than a decade of National Institute of Dental and Craniofacial Research and National Institute of Health-supported research make SaliMark OSCC the world’s most scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma.
PeriRx will employ several ways to inform Yankee Dental Congress attendees about SaliMark OSCC, which is scheduled to ship via several national dental distributors before the end of Q1.
In addition to exhibiting at booth No. 1746, PeriRx will be introducing SaliMark OSCC in the following ways:
Free CE Course: "Oral Cancer Risk Assessment: Ready for Primetime" (course code 215TL) will provide 2 CE credits and will be presented by PeriRx Chief Medical Officer Jack Martin, MD on Thursday, 1/29/15 from 2:00 p.m. to 4:00 p.m. in Room No. 260
Free SaliMark OSCC Test Kit: Any dental practice owner who pre-registers and creates a PeriRx online ordering account, will receive one free SaliMark™ test Kit in order to get familiar with the test, the protocol, and the lab results. Simply visit http://perirxsecure.com/register.php to register your practice and set up an account.
Dr. Paul Feuerstein’s High-Tech Playground: Every year at Yankee, leading dental technology expert Dr. Paul Feuerstein assembles the latest dental equipment and technology in an informal, no pressure setting right on the exhibit hall floor (Booth No. 444). PeriRx will be proudly participating during the following times:
- Thursday, 1/29/15: Tabletop 2:00 p.m. to 4:00 p.m. with 10-minute presentation at 2:30 p.m.
- Saturday, 1/31/15: Tabletop 10:00 a.m. to 12:30 p.m. with 10-minute presentation at 10:00 a.m.
References 1 & 2 : National Cancer Institute. SEER Stat Fact Sheets: Oral Cavity and Pharynx Cancer. Bethesda, MD: National Cancer Institute; 2012. Accessed at http://seer.cancer.gov/statfacts/html/oralcav.html. Archived by WebCite at http://www.webcitation.org/6Rbi0VGeW)
About SaliMark OSCC
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles. The SaliMark OSCC test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer. Recently, the SaliMark OSCC test underwent a PRoBE (prospective-specimen-collection, retrospective-blinded-evaluation) design study which is the most rigorous biomarker validation available. In addition, PeriRx successfully completed a validation of the mRNA markers at the University of Michigan, Michigan State University and the St. Johns Providence Health System in Detroit.
About PeriRx LLC
Based in Broomall, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, noninvasive oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management. The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO and founder Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist. PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.